STX.L
Price:
$3.787
Market Cap:
$39.45M
Shield Therapeutics plc, a specialty pharmaceutical company, engages in the development and commercialization of clinical stage pharmaceuticals to treat unmet medical needs. The company's lead product is Accrufer/Feraccru, a non-salt based oral therapy for the treatment of iron deficiency with or without anemia in adults. It also develops PT20, a novel iron-based phosphate binder that has completed its Phase II pivotal study for the treatment of hyperphosphatemia in patients with chronic kidney disease. The company was founded in 2008 and is based in Gateshead, the United Kingdom.
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
2016-02-26
Stock Exchange
LSE
Ticker
STX.L
According to Shield Therapeutics plc’s latest financial reports and current stock price. The company's current PE Ratio is -1.89. This represents a change of 171.63% compared to the average of -0.70 of the last 4 quarters.
The mean historical PE Ratio of Shield Therapeutics plc over the last ten years is -10.32. The current -1.89 PE Ratio has changed 1.73% with respect to the historical average. Over the past ten years (40 quarters), STX.L's PE Ratio was at its highest in in the June 2020 quarter at 13.59. The PE Ratio was at its lowest in in the June 2019 quarter at -16.65.
Average
-10.32
Median
-5.67
Minimum
-29.14
Maximum
-0.41
Discovering the peaks and valleys of Shield Therapeutics plc PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 322.56%
Maximum Annual PE Ratio = -0.41
Minimum Annual Increase = -91.36%
Minimum Annual PE Ratio = -29.14
Year | PE Ratio | Change |
---|---|---|
2024 | -1.15 | -20.98% |
2023 | -1.45 | 257.72% |
2022 | -0.41 | -91.36% |
2021 | -4.70 | -83.85% |
2020 | -29.14 | 18.95% |
2019 | -24.50 | 20.22% |
2018 | -20.38 | 206.73% |
2017 | -6.64 | -44.63% |
2016 | -12.00 | 322.56% |
2015 | -2.84 | -28.92% |
The current PE Ratio of Shield Therapeutics plc (STX.L) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-1.00
5-year avg
-7.37
10-year avg
-10.32
Shield Therapeutics plc’s PE Ratio is greater than Celadon Pharmaceuticals Plc (-2.27), less than N4 Pharma Plc (-1.07), greater than Avacta Group Plc (-4.05), less than Genedrive Plc (-0.37), greater than ImmuPharma plc (-5.97), less than ANGLE plc (-1.14),
Company | PE Ratio | Market cap |
---|---|---|
-2.27 | $9.23M | |
-1.07 | $3.30M | |
-4.05 | $124.19M | |
-0.37 | $8.37M | |
-5.97 | $9.88M | |
-1.14 | $16.12M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Shield Therapeutics plc using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Shield Therapeutics plc or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Shield Therapeutics plc's PE Ratio?
How is the PE Ratio calculated for Shield Therapeutics plc (STX.L)?
What is the highest PE Ratio for Shield Therapeutics plc (STX.L)?
What is the 3-year average PE Ratio for Shield Therapeutics plc (STX.L)?
What is the 5-year average PE Ratio for Shield Therapeutics plc (STX.L)?
How does the current PE Ratio for Shield Therapeutics plc (STX.L) compare to its historical average?